Comparing predictors of conversion and decline in mild cognitive impairment
- 20 July 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 75 (3), 230-238
- https://doi.org/10.1212/wnl.0b013e3181e8e8b8
Abstract
Objective: A variety of measurements have been individually linked to decline in mild cognitive impairment (MCI), but the identification of optimal markers for predicting disease progression remains unresolved. The goal of this study was to evaluate the prognostic ability of genetic, CSF, neuroimaging, and cognitive measurements obtained in the same participants. Methods: APOE ε4 allele frequency, CSF proteins (Aβ1-42, total tau, hyperphosphorylated tau [p-tau181p]), glucose metabolism (FDG-PET), hippocampal volume, and episodic memory performance were evaluated at baseline in patients with amnestic MCI (n = 85), using data from a large multisite study (Alzheimer's Disease Neuroimaging Initiative). Patients were classified as normal or abnormal on each predictor variable based on externally derived cutoffs, and then variables were evaluated as predictors of subsequent conversion to Alzheimer disease (AD) and cognitive decline (Alzheimer's Disease Assessment Scale–Cognitive Subscale) during a variable follow-up period (1.9 ± 0.4 years). Results: Patients with MCI converted to AD at an annual rate of 17.2%. Subjects with MCI who had abnormal results on both FDG-PET and episodic memory were 11.7 times more likely to convert to AD than subjects who had normal results on both measures (p ≤ 0.02). In addition, the CSF ratio p-tau181p/Aβ1-42 (β = 1.10 ± 0.53; p = 0.04) and, marginally, FDG-PET predicted cognitive decline. Conclusions: Baseline FDG-PET and episodic memory predict conversion to AD, whereas p-tau181p/Aβ1-42 and, marginally, FDG-PET predict longitudinal cognitive decline. Complementary information provided by these biomarkers may aid in future selection of patients for clinical trials or identification of patients likely to benefit from a therapeutic intervention.This publication has 41 references indexed in Scilit:
- Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimer DiseaseAmerican Journal Of Neuroradiology, 2010
- Alzheimer's disease: progress in predictionThe Lancet Neurology, 2010
- Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCINeurobiology of Aging, 2009
- MRI and CSF biomarkers in normal, MCI, and AD subjectsNeurology, 2009
- MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkersBrain, 2008
- The Alzheimer's disease neuroimaging initiative (ADNI): MRI methodsJournal of Magnetic Resonance Imaging, 2008
- PENN Biomarker Core of the Alzheimer’s Disease Neuroimaging InitiativeNeurosignals, 2007
- Prediction and longitudinal study of CSF biomarkers in mild cognitive impairmentNeurobiology of Aging, 2007
- Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairmentJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984